David L. Bajor

Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

Robert H. Vonderheide, Keith T. Flaherty, Magi Khalil et al. · Journal of Clinical Oncology · 2007 · 513 citations

Medicine, Oncology, Pharmacology +16

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

Rafael Winograd, Katelyn T. Byrne, Rebecca A. Evans et al. · Cancer Immunology Research · 2015 · 468 citations · Full text

Life Sciences, Immunology, Oncology +17

Sotorasib in <i>KRAS</i> p.G12C–Mutated Advanced Pancreatic Cancer

John H. Strickler, Hironaga Satake, Thomas J. George et al. · New England Journal of Medicine · 2022 · 468 citations · Full text

Medicine, Oncology, Pharmacology +11

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

John H. Strickler, Andrea Cercek, Salvatore Siena et al. · The Lancet Oncology · 2023 · 245 citations · Full text

Medicine, Oncology, Pharmacology +10

Lack of immunoediting in murine pancreatic cancer reversed with neoantigen

Rebecca A. Evans, Mark S. Diamond, Andrew J. Rech et al. · JCI Insight · 2016 · 181 citations · Full text

Life Sciences, Immunology, Oncology +17